Donor-specific antibodies. Clinical relevance of antibodies detected in lymphocyte crossmatches.
Positive donor crossmatches due to lymphocytotoxic antibodies generally have an adverse effect on allograft survival, but with numerous variations. Different laboratory techniques used to characterize lymphocytotoxic antibody, new antibody systems, such as those incited by endothelial/monocyte and epithelial antigens, the variable tempos and histopathologic changes of early rejections caused by these antibodies, and the specific features imposed by each organ, all combine to make the once simple crossmatch test a complex, clinical and laboratory crossroads, that directs the initial and perhaps ultimate course of the allograft. An integrated assessment of these factors is provided in this article.
Braun
W E
WE
Department of Hypertension and Nephrology, Cleveland Clinic Foundation, Ohio.
D000888:Antibodies, Anti-Idiotypic / Q000302:isolation & purification; D000918:Antibody Specificity; D000961:Antilymphocyte Serum / Q000302:isolation & purification*; D006084:Graft Rejection / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D014019:Tissue Donors; D014181:Transplantation Immunology
D000888:Antibodies, Anti-Idiotypic; D000961:Antilymphocyte Serum